EMA RELEASES BATCH OF ADVANCED THERAPY MEDICINAL PRODUCT CLASSIFICATIONS
March 1st, 2014
THE EUROPEAN Medicines Agency (EMA) has released six detailed guidelines on classifying new cutting edge advanced therapy medicinal products. These include those based on ex-vivo autologous corneal epithelium containing stem cells, for instance. Another definition focuses on medicines based on viable autologous keratinocytes and melanocytes grown on an AS210 matrix. And the other four are pharmaceuticals using allogeneic activated leukocytes; ex-vivo expanded autologous skeletal myoblasts; retinal pigment epithelium cells derived from human induced pluripotent ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.